Drug major Lupin today appointed Martin Mercer as President of its Latin American business with immediate effect.
In his new role, Mercer will assume full responsibility for the company's Latin American business including the overall strategy for its generics and specialty business in Brazil, Mexico, Venezuela, Colombia and Argentina, Lupin Ltd said in a statement.
Lupin CEO Vinita Gupta said: "We believe that Martin's rich experience in Latin America will be an asset when it comes to expanding and strengthening Lupin's businesses in the region."
The Latin American region is a market of strategic focus for the company and one of the fastest growing pharmaceutical markets globally, she added.
Mercer, who will be based at Naples, Florida, joins Lupin from Astellas Pharma where he was the Head of Latin America.
Prior to that, he has worked at Valeant as Head of Latin America and International business as well as Glaxo in regional management positions.
Other than successfully building and scaling large businesses in diverse geographies of Latin America, Mercer has significant experience in acquisition integration, change management and restructuring, business development and new product development.
Last week, the Mumbai-headquartered firm had appointed Fabrice Egros as President, Asia Pacific and Japan.
